Loading...
01/09 22:53
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call and Q&A reflect a positive outlook, with strong product adoption, strategic cost optimization, and promising guidance for Q4. Despite some headwinds, the company anticipates a strong Q4, supported by effective marketing strategies and expected seasonal demand. The positive sentiment is further bolstered by the focus on expanding training for Evolysse, strategic bundling with Jeuveau, and the potential for long-term revenue growth. However, the lack of specific guidance on tariffs and sales splits introduces some uncertainty, warranting a cautious but optimistic rating.
Global net revenue for Q3 2025 $69 million, a 13% increase over Q3 2024. The growth was driven by the introduction of Evolysse and growth in global Jeuveau.
Global Jeuveau revenue for Q3 2025 $63.2 million. Growth was supported by record consumer demand through the Evolus Rewards program and positive unit growth in the U.S. and internationally.
Evolysse revenue for Q3 2025 $5.7 million. This marked the strongest HA filler debut in over a decade, with sequential demand growth after initial stocking by accounts in the launch quarter.
Reported gross margin for Q3 2025 66.5%. Adjusted gross margin was 67.6%, excluding the amortization of intangibles.
GAAP operating expenses for Q3 2025 $57.3 million, up from $55.5 million in Q2 2025. The increase was partly due to the absence of a $3.9 million reduction related to the revaluation of the contingent royalty obligation in Q2.
Non-GAAP operating expenses for Q3 2025 $49.7 million, down from $54 million in Q2 2025. This reduction reflects strategic cost structure optimization and excludes restructuring charges and other adjustments.
Non-GAAP operating loss for Q3 2025 $3.1 million, compared to $6.7 million in Q3 2024. The improvement was due to operating expense reduction and timing of a major customer event.
Cash balance at the end of Q3 2025 $43.5 million, down from $61.7 million at the end of Q2 2025. The decrease was primarily due to pulling forward inventory purchases ahead of potential tariffs on pharmaceuticals.
Evolysse launch: More than 4,000 customers have completed hands-on training, with the majority purchasing Evolysse. Accounts trained twice showed a 100% increase in purchasing volume. Evolysse generated $5.7 million in Q3 revenue and $15.5 million since launch, marking the strongest HA filler debut in over a decade.
Evolysse Sculpt: PMA submitted to the FDA for advanced injectable HA sculpt for mid-face volume restoration. Approval anticipated in the second half of 2026. Clinical trials showed statistical superiority over Restylane Lyft with a threefold difference in efficacy at 24 months.
International market expansion: Entered two new markets in 2025. Mature markets like the U.K. are growing at high rates, with market share mirroring U.S. uptake.
U.S. market performance: Jeuveau outperformed the U.S. aesthetic market, growing unit volume year-to-date despite market challenges. Strengthened 14% share of the U.S. market.
Consumer loyalty program: Evolus Rewards program grew to 1.3 million members, up 34% year-on-year, with 70% returning customers. Total redemptions grew 34% compared to the prior year quarter.
Expense management: Rebased expenses, reflected in Q3 results, positioning the company for sustainable profitability by 2026.
Portfolio bundling strategy: Introduced Evolus portfolio bundle in Q4 2025 to reward practices growing across both Jeuveau and Evolysse, aiming to drive market share gains.
Pipeline development: Broader launch of a steam in Europe planned for the first half of 2026. Lyft HA injectable trial ongoing, with approval and launch expected in 2027.
Consumer Spending Challenges: The U.S. aesthetic market is facing near-term challenges related to consumer spending, which could impact demand for injectables and overall revenue growth.
Tariff Uncertainty: Potential tariffs on pharmaceuticals, including Jeuveau, and a 15% tariff on Evolysse under the EU trade agreement could increase costs and impact financial performance.
Regulatory Approval Risks: The FDA approval process for Evolysse Sculpt and other products carries inherent risks, including potential delays or non-approval, which could affect product launch timelines and revenue projections.
Inventory Management: The company has pulled forward inventory purchases to mitigate potential tariff impacts, which could strain cash flow and working capital.
Market Competition: Competitive pressures in the aesthetics market, including bundled offerings from competitors, could challenge Evolus' market share and pricing strategies.
Economic Uncertainty: Broader economic uncertainties could affect consumer behavior and spending on aesthetic treatments, impacting revenue growth.
Profitability Timeline: Evolus aims to achieve profitability in the fourth quarter of 2025 and sustainable annual profitability beginning in 2026.
Market Demand and Trends: The U.S. aesthetic market is showing early signs of stabilization, with demand for injectables expected to improve sequentially. Jeuveau is poised to regain momentum as the overall toxin category returns to growth.
Revenue Projections: Evolus reiterates its 2025 revenue guidance of $295 million to $305 million, representing 11% to 15% growth over 2024 results. Evolysse is expected to contribute 10% to 12% of total revenue for the full year 2025.
Product Launches and Approvals: Evolysse Sculpt, an advanced injectable HA sculpt for mid-face volume restoration, is anticipated to receive FDA approval in the second half of 2026. A broader launch of a steam in Europe is planned for the first half of 2026. The Lyft HA injectable trial is ongoing, with approval and launch expected in 2027.
Portfolio Bundling Strategy: Evolus has introduced its first portfolio bundle to reward practices that grow across both Jeuveau and Evolysse, aiming to drive market share gains and compete against competitive bundles.
Tariff Impact Mitigation: Evolus is proactively addressing potential tariff impacts on pharmaceuticals, including Jeuveau, and has sufficient inventory to avoid near-term disruptions. Evolysse is subject to a 15% tariff under a new trade agreement with the EU, which has been incorporated into financial outlooks.
The selected topic was not discussed during the call.
The earnings call and Q&A reflect a positive outlook, with strong product adoption, strategic cost optimization, and promising guidance for Q4. Despite some headwinds, the company anticipates a strong Q4, supported by effective marketing strategies and expected seasonal demand. The positive sentiment is further bolstered by the focus on expanding training for Evolysse, strategic bundling with Jeuveau, and the potential for long-term revenue growth. However, the lack of specific guidance on tariffs and sales splits introduces some uncertainty, warranting a cautious but optimistic rating.
The earnings call summary indicates mixed signals: strong market share growth and product launches are positive, but macroeconomic factors and reduced consumer demand are concerning. The Q&A reveals uncertainties, such as the impact of promotions and consumer sentiment. Despite positive long-term targets and a strong product launch, the immediate outlook is tempered by economic challenges and cautious guidance adjustments. Without a clear market cap, it's challenging to predict a strong movement, hence a neutral rating is appropriate.
The earnings call presents mixed signals: while there is strong revenue growth and improved operational efficiency, challenges such as negative consumer sentiment towards fillers, competitive pressures, and economic factors affecting demand are concerning. The positive aspects include strategic debt refinancing, stable gross margins, and a strong customer reorder rate. However, the cautious market outlook and operational challenges balance these positives. The Q&A section reveals confidence in guidance but also highlights market pressures. Without a clear market cap, the overall sentiment is neutral, suggesting a stock price movement between -2% to 2%.
The earnings call presents a mixed outlook. While there is strong revenue growth and positive guidance for 2025, challenges such as reduced market growth expectations, tariff impacts, and increased operating expenses pose risks. Additionally, the lack of a share repurchase program and management's unclear responses on certain issues add uncertainty. The Q&A session highlights some positive shifts towards hyaluronic acids and confidence in guidance, balancing the negative factors. Thus, a neutral sentiment is appropriate, indicating a likely stock price movement between -2% and 2%.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
